Pharmacist Pain E-Consults That Result in a Therapy Change
Danielle M. Miller, PharmD; and Tracy L. Harvey, PharmD, BCPS, CPE

Pain specialty pharmacists can provide support to prescribing primary care providers and enable changes in therapy.

The enormity of chronic pain among the veteran population makes pain management within the VA a critical issue. Of the veterans returning from Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF), chronic pain is the most common report. Of equal concern is the lack of available pain specialists in the U.S. There are <4,000 pain specialists in the U.S., and even fewer pain specialists are available within the VA system, making it difficult for veterans to access pain care and timely treatment.

Furthermore, one of the biggest challenges surrounding pain management is the lack of proper training received by generalists and primary care providers (PCPs). Whereas opioid therapy was previously prescribed mainly by specialists and mainly to cancer patients, that is no longer the case. Today, non-specialists frequently prescribe opioids, and 95% of long-acting opioids are for chronic, non-cancer pain. In a majority of reviewed pain electronic consultations (e-consults) completed by the pain specialty pharmacist at the Bay Pines VA Healthcare System (BPVAHCS), the patient was not currently receiving opioid therapy, suggesting PCPs’ lack of comfort and training in chronic pain management. Effective and appropriate pain management from the patient perspective and confidence and reassurance from the prescriber standpoint cannot be successfully achieved without drastic improvements in education and training.

The inception of the E-Consult Pain Service arose from a grant from VA National Innovations in Consult Management to 3 VA facilities in Florida: BPVAHCS; Orlando VAMC, and North Florida/South Georgia Veterans Health Systems. At the Orlando VAMC, PCPs needed advice on pain management for patients while they waited to see a pain clinic specialist, so a Pain Help Line was implemented to provide immediate consultations, but miscommunication between recommendations given and their implementation limited its utility. That eventually led to an E-Consult Pain Service, which provided formal full chart reviews for pain management cases.

The E-Consult Pain Service program included 2 full-time pharmacists, a part-time pain psychologist, and a pain physician. Its goal was to assist PCPs with patient-specific pain management recommendations. The consult service did not replace specialty pain clinics, nor was it meant to provide continual pain management. Additional, separate pain e-consults could be scheduled as a follow-up to a previous consult or for new pain management issues. Although the recommendations in the consults were available for the provider’s use, it was at the provider’s discretion as to whether the recommendations were accepted and implemented.

THE E-CONSULT PAIN SERVICE
The E-Consult Pain Service at the BPVAHCS started July 2011. Staffed by a full-time physician and pain specialty pharmacist, the program provides electronic chart review and recommendations to PCPs regarding complex pain management issues. About three-fourths of their time was spent directly on the consults, which took between 1 and 5 business days to complete. Their remaining time was spent on educational initiatives and administrative duties.

The BPVAHCS is a complexity level 1a facility providing comprehensive health care. The facility comprises a 192-acute care bed hospital (includes intensive care, medical, surgical, and psychiatric units);
a 112-bed community living center; a 65-bed domiciliary; and a 34-bed residential treatment program.

Initially, the program was developed to provide pain management support to PCPs in the community-based outpatient clinics (CBOCs) but expanded to all BPVAHCS providers. With the expansion, the program helped reduce a 3-month delay for patients waiting to be seen in the pain clinic. Goals of the program included improving patient outcomes and safety while minimizing opioid therapy risks. These goals are met through an individual case consultation as well as formal educational programs for providers.

The purpose of this study was to obtain data evaluating the characteristics of recommendations made by a pharmacist through pain e-consults at the BPVAHCS and the percentage of consults that resulted in a change in therapy. Future research is warranted to provide clarity on why specific recommendations are or are not being accepted, patient outcomes, and PCPs’ perception on the program’s utility.

**METHODS**

An institutional review board-exempt, retrospective chart review was conducted at the BPVAHCS to determine the percentage of patients whose pain regimen changed as a result of a pain e-consult completed by a pain specialty pharmacist. Although the BPVAHCS E-Consult Pain Service comprised a physician and a pain specialty pharmacist, this study was focused solely on the role and recommendations by the pharmacist. The characteristics of those recommendations and their acceptance/rejection rate were then recorded. Of note, the physician completed separate e-consults, and the frequency of input by the physician on pharmacist recommendations was not collected.

Patients who had a pain e-consult regarding chronic, noncancer pain between January 1, 2012, and March 31, 2012, were identified for inclusion in the study. Charts were selected based on consults submitted by providers. No consults for headaches were requested in the selected time frame.

**Chronic pain** is defined as persistent pain with or without an identifiable organic cause, lasting longer than 3 to 6 months. Use of the term *chronic pain* throughout this article refers to chronic, noncancer pain. Criteria for exclusion included patients who received a pain e-consult but died before September 30, 2012.

**Data Collection**

Patients identified for inclusion had their charts reviewed 6 months after completion of the consult in order to allow sufficient time for potential implementation of recommendations. Patient demographics, name and dose of pain medications, requesting practitioner, type of chronic

---

**Figure 1. Pharmacologic Recommendations by Pain Specialty Pharmacist**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Patients, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce opioid</td>
<td>48</td>
</tr>
<tr>
<td>D/C opioid</td>
<td>52</td>
</tr>
<tr>
<td>Add/change SNRI</td>
<td>79</td>
</tr>
<tr>
<td>Add/change AED</td>
<td>75</td>
</tr>
<tr>
<td>Add/change NSAID</td>
<td>45</td>
</tr>
<tr>
<td>Add/change topical</td>
<td>80</td>
</tr>
<tr>
<td>Taper or D/C BZD</td>
<td>13</td>
</tr>
</tbody>
</table>

Abbreviations: AED, antiepileptic drug; BZD, benzodiazepine; D/C, discontinue; NSAID, nonsteroidal anti-inflammatory drug; SNRI, selective norepinephrine reuptake inhibitor.

*N = 122.*
pain, recommendation of pain e-consult, and consult outcome(s) were recorded for all participants.

The primary outcome of the study was the percentage of recommendations, both pharmacologic and nonpharmacologic, made by the pain specialty pharmacist and accepted and implemented by the consulting provider.

RESULTS
A total of 127 patient charts were identified for inclusion. Five patients died prior to September 30, 2012, and were excluded from the study, leaving 122 charts for review. All 122 charts reviewed by the pain specialty pharmacist included recommendations. Most patients were male (95.1%) and white (75.6%). The most common source of chronic pain was back pain (66.4%) (Table).

Primary Outcome
The pain specialty pharmacist pharmacologic treatment option recommendations varied significantly: add and/or change topical (80% of the 122 patients); add and/or change selective norepinephrine reuptake inhibitor (SNRI) (79%); add and/or change antiepileptic drug (AED) therapy (75%); discontinue opioid (52%); reduce opioid (48%); add and/or change nonsteroidal anti-inflammatory drug (NSAID) (45%); and taper/discontinue benzodiazepine (BZD) (13%) (Figure 1).

Primary care providers could choose to accept or ignore the recommendation, and of all the pharmacologic recommendations made, about 50% were implemented. The rate of PCP implementation of the pharmacist's recommendations varied: add and/or change AED therapy (54%); add and/or change topical (44%); reduce opioid (42%); discontinue opioid (41%); taper/discontinue BZD (38%); add and/or change SNRI (36%); and add and/or change NSAID (33%).

Despite the most frequent recommendations made by pharmacists, the 3 most accepted and implemented by providers were addition and/or change in AED therapy, addition and/or change in topical therapy, and a decrease in opioid dose. Changes in therapy were identified as either a dose decrease or increase in the existing agent, whereas a new agent was considered an addition to existing pain therapy.

The rates of nonpharmacologic recommendations made by the pharmacist were as follows: ordering additional labs, primarily vitamin D and testosterone levels (55%); referral to physical therapy (PT) (54%); weight loss (51%); smoking cessation (43%); specialty referral (42%); order new urine drug screen (UDS) (35%); referral to pain school education program (26%); transcutaneous electrical nerve stimulation (TENS) (25%); referral to the substance abuse treatment program (SATP) (15%); and update opioid agreement (OA) (9%) (Figure 2).

Nonpharmacologic treatment acceptance rates were as follows: order new UDS (67%); update OA (45%); referral to SATP (33%); referral to PT (33%); order additional labs, primarily vitamin D and testosterone levels (27%); specialty referral (22%); TENS (19%); weight loss (18%); referral to pain school education program (16%); smoking cessation (6%); and music therapy (0%). The top 3 accepted recommendations were obtained of a new UDS; updating the patient’s OA; and tied for third, referral to PT or the SATP.

DISCUSSION
Including a pharmacist as part of a pain e-consult team may provide support to PCPs for managing chronic pain as well as for measuring improved adherence to VA/DoD guidelines for chronic pain. Pharmacists can offer recommendations for nontraditional pain therapies that PCPs may be unaware of or are unfamiliar with, such as the use of nonnarcotic agents and various nonpharmacologic options. For example, recommend testing for vitamin D levels. Vitamin D deficiency is common among the general population, and a project completed by Roesel and Engel specifically addressed vitamin D deficiency and pain in OEF/OIF veterans. Other studies have shown a correlation between vitamin D supplementation and a reduction in musculoskeletal pain or the association between low vitamin D levels and hypersensitivity in patients with chronic pain. Studies have also demonstrated a link between vitamin D deficiency and depression, which is well known to augment or increase...
patient awareness of somatic reports, like pain. Of all the pharmacologic recommendations made, about 50% were implemented. It is noteworthy to mention that although a change/addition in SNRI therapy was recommended by the pharmacist 79% of the time, it was accepted and implemented by the PCP only one-third of the time. Many veterans have co-occurring mental health conditions, which are often managed by a psychiatrist, who is typically not the consulting provider (the PCP is). The PCP may be hesitant to change antidepressant therapy for fear of destabilizing the patient or because the PCP was not the antidepressant therapy prescriber. However, the incidence of co-occurring seizure disorders among veterans is much less than that of mental health disorders, making PCPs much more likely to accept and/or change AEDs. Interestingly, the majority of pain specialty pharmacist e-consults involved chronic pain management, further demonstrating the lack of comfort, time, and/or proper training for PCPs in general pain management.

Although the e-consult program at the BPVAHCS consisted solely of a physician and a pain specialty pharmacist, the purpose of this project was to evaluate the characteristics of recommendations made by a pharmacist and the percentage of consultations that resulted in a therapy change. The physician was responsible for separate consults, and their recommendations were not collected. However, it is important to recognize that the pain specialty pharmacist and physician performed identical roles on the team, each recommending both pharmacologic and nonpharmacologic treatment options in every consult.

**Related Programs**

The VA Boston Healthcare System (VABHS) is composed of 3 main facilities and 5 CBOCs across eastern Massachusetts. Although veterans in the eastern part of the state are able to receive primary care at a CBOC, specialty care is provided primarily at 2 of the main locations in the Boston area. Therefore, the VABHS began an e-consult program in order to facilitate patient access to specialty providers for patients unable to participate in a face-to-face visit.

The purpose of the VABHS study was to examine the implementation and provider perception of an e-consult program within a large VA system, to provide timely patient access to specialty care. The pilot program was initiated in 2 specialty clinics in 2011 but expanded to 12 specialty clinics within 9 months. The specialty clinics included allergy, cardiology, endocrinology, gastroenterology, hematology, infectious disease, nephrology, oncology, palliative care, pulmonary disease, rheumatology, and sleep medicine. Outcomes of the VABHS e-consult program revealed that a majority of PCPs were satisfied with the use of e-consults.
whereas specialists were less satisfied. The PCP-perceived benefits to patients included avoidance of unnecessary travel, faster clinical input, and avoidance of unnecessary copays.9

Like the VABHS, the use of pain e-consults at BPVAHCS helps reduce the burden of face-to-face clinic visits and eliminate accessibility barriers for veterans. This study differs from the VABHS in that PCPs requested onetime consults focused solely on pain management. The pain specialty pharmacist at BPVAHCS did not provide longitudinal care; measure patient outcomes, such as satisfaction, reduction in pain, or improved functionally; or examine provider satisfaction. Additionally, unlike the BPVAHCS program, there was no indication whether a pharmacist played a role in the program.9

Other studies have explored the role of a pain pharmacist in the inpatient setting offering consults on patient-controlled analgesia and in patients with a history of substance abuse.10,11 Another recent study similarly looked at the effectiveness of a pharmacist-led medication review in chronic pain management. The aim was to assess patient outcomes: decrease in pain intensity and improvement in physical functioning.12 Another study involving a nurse and pharmacist-led chronic pain clinic in a primary care setting conducted in England showed improvement in patient-reported pain and reduction in secondary referrals.13

LIMITATIONS
Limitations of the study included short study duration (6 months); use of a newly implemented E-Consult Pain Service; lack of pharmacist follow-up on acceptance/rejection of their recommendation; inability to determine patient outcome(s), as consults were for a single point in time, regarding a therapy recommendation; lack of access to non-VA medications; and patient refusal to change current pain regimen.

Patient refusal inhibited providers from implementing therapy changes recommended by the pharmacist and therefore could have negatively impacted study outcomes. Raw data were used for this study, and there were no statistical analyses conducted. Furthermore, lack of other formal e-consult programs within BPVAHCS to compare the acceptance/rejection of pharmacist recommendations for other conditions and lack of a third-party review of pharmacist recommendations to ensure standard of care may have limited this study.

FUTURE RESEARCH
As the E-Consult Pain Service continues, research regarding the value of the pain specialty pharmacist may be warranted. Additional research is needed to identify the reasons that recommendations were accepted or ignored, whether the recommendations were beneficial to the patients, and the PCPs’ perception on the usefulness of a pain e-consult program. When the program started, 14% of patients at BPVAHCS were taking opioids. The pain e-consult program handled a small percentage of these patients.

The authors considered proactively reviewing all patients on > 100 mg morphine equivalents of opioids daily but did not have adequate staff to support the review. It may be helpful to identify those patients taking opioids but do not have a consult. The role of the pain e-consult pharmacist may be expanded to assist PCPs, including leading patient education classes to explain the concept and purpose of the opioid treatment agreement; reinforcing expected behaviors and outcomes of patients prescribed opioids; assisting providers with interpreting UDSs and notifying providers of aberrant behaviors; and educating providers on opioid risk mitigation through seminars or academic detailing.

Furthermore, future research may be warranted to determine the prospective role of a pain specialty pharmacist on longitudinal measures, such as pain outcomes, patient satisfaction, improvement in quality of life and/or function, as well as to determine provider perspective and satisfaction of the program. Finally, it would be interesting to compare and contrast the recommendations and outcomes between the pharmacist and physician team at the BPVAHCS.

CONCLUSION
The addition of a pain specialty pharmacist as part of the E-Consult Pain Service seems to provide support to prescribing PCPs in general chronic pain management, as well as measuring improved adherence to VA/DoD guidelines for chronic pain.

Acknowledgements
This material is the result of work supported with resources and the use of facilities at the Bay Pines VA Healthcare System.

Author Disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the
Pain E-Consults

complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

REFERENCES